Represents the initial period of the collaborative agreement.

No definition available.

Name:	imgn_CollaborativeArrangementAgreementTerm
Namespace Prefix:	imgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of single-target licenses the company has right to use.

+ References

No definition available.

+ Details

Name:	imgn_NumberOfSingleTargetLicenses
Namespace Prefix:	imgn_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 8
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044

+ Details

Name:	us-gaap_ContractWithCustomerAssetGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2(a),(d))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_CostOfGoodsAndServicesSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=imgn_TakedaOncologyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_DevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_PhaseIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_PhaseIIClinicalTrialMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_RightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=imgn_OptionToExpandScopeOfRightToTestMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_LicenseAndMilestoneFeesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_UpfrontPaymentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_ResearchAndDevelopmentSupportMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=imgn_ClinicalMaterialsRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Agreements - Takeda (Details)	1 Months Ended			3 Months Ended												12 Months Ended
Agreements - Takeda (Details)	May 31, 2018 USD ($)	Mar. 31, 2018 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2019 USD ($)	Sep. 30, 2019 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Sep. 30, 2018 USD ($)	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2019 USD ($) item	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Jun. 30, 2016 USD ($)
Collaborative Agreements disclosures
Revenue from contract with customer				$ 44,864,000	$ 13,281,000	$ 15,542,000	$ 8,584,000	$ 13,416,000	$ 10,928,000	$ 9,287,000	$ 19,815,000	$ 39,448,000	$ 8,480,000	$ 39,020,000	$ 28,499,000	$ 82,271,000	$ 53,446,000	$ 115,447,000
ASU 2014-09 \| Adjustments due to new guidance
Collaborative Agreements disclosures
Revenue from contract with customer																	5,000,000
Takeda
Collaborative Agreements disclosures
Number of single-target licenses \| item																1
Potential milestone payment			$ 210,000,000
Takeda \| Development milestones
Collaborative Agreements disclosures
Potential milestone payment			30,000,000
Takeda \| Phase 1 clinical trial \| ASU 2014-09 \| Adjustments due to new guidance
Collaborative Agreements disclosures
Revenue from contract with customer	$ 5,000,000
Takeda \| Phase 2 clinical trial
Collaborative Agreements disclosures
Potential milestone payment				10,000,000												$ 10,000,000
Takeda \| Regulatory milestones
Collaborative Agreements disclosures
Potential milestone payment			85,000,000
Takeda \| Milestone payments
Collaborative Agreements disclosures
Potential milestone payment			$ 95,000,000
Takeda \| Right-to-test agreement
Collaborative Agreements disclosures
Term of agreement			3 years
Potential milestone payment			$ 4,000,000
Takeda \| Option to expand scope of right-to-test
Collaborative Agreements disclosures
Potential milestone payment			8,000,000
License and milestone fees
Collaborative Agreements disclosures
Revenue from contract with customer				$ 29,551,000	$ 79,000	5,079,000	79,000	1,747,000	672,000	1,321,000	11,540,000	29,580,000	79,000	31,080,000	18,730,000	34,788,000	15,280,000	79,469,000
License and milestone fees \| Takeda
Collaborative Agreements disclosures
Revenue from contract with customer		$ 10,900,000																	$ 8,600,000
Potential milestone payment			210,000,000
Upfront payment \| Takeda
Collaborative Agreements disclosures
Revenue from contract with customer			$ 20,000,000
Research and development support
Collaborative Agreements disclosures
Revenue from contract with customer						$ 51,000	$ 17,000	218,000	388,000	388,000	383,000	452,000	650,000	902,000	1,478,000	68,000	1,377,000	3,482,000
Research and development support \| Takeda
Collaborative Agreements disclosures
Costs of services and materials																	199,000	913,000
Clinical materials revenue
Collaborative Agreements disclosures
Revenue from contract with customer								$ 2,170,000	$ 1,427,000	$ 336,000	$ 702,000	$ 1,829,000	$ 1,248,000	$ 599,000	$ 678,000		4,635,000	4,354,000
Clinical materials revenue \| Takeda
Collaborative Agreements disclosures
Costs of services and materials																$ 0	$ 650,000,000,000	$ 2,100,000